Kabazitaksel Viatris

Cabazitaxel, the active ingredient in Kabazitaksel Viatris, is a taxane presented as an intravenous formulation for intravenous use. It is indicated for the treatment of metastatic castration‑resistant prostate cancer in patients who have progressed after prior chemotherapy. GNH USA supplies Kabazitaksel Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Kabazitaksel Viatris is a taxane chemotherapy used in the management of advanced prostate cancer that no longer responds to hormonal therapy. - Metastatic castration‑resistant prostate cancer: improves overall survival and disease control in patients previously treated with docetaxel.

Cabazitaxel may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced neutrophil count increasing infection risk. - Anemia: lowered red blood cell levels causing fatigue. - Fatigue: general tiredness and weakness. - Nausea and vomiting: gastrointestinal upset. - Alopecia: hair loss on scalp and body. - Diarrhea: loose stools and abdominal cramping.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils requiring urgent care. - Severe infections: sepsis or pneumonia. - Hypersensitivity reactions: rash, bronchospasm, or anaphylaxis. - Peripheral neuropathy: tingling or loss of sensation in extremities. - Cardiac toxicity: arrhythmias or reduced heart function. - Hepatotoxicity: marked elevation of liver enzymes.

Before initiating therapy, clinicians should evaluate patient-specific risk factors and monitor for toxicity. - Blood count monitoring: perform complete blood counts before each dose and as clinically indicated. - Liver function assessment: check hepatic enzymes and bilirubin prior to treatment. - Hypersensitivity evaluation: assess history of allergic reactions to taxanes. - Elderly patients: use caution and consider dose adjustments due to increased susceptibility. - Severe neutropenia: avoid use in patients with active grade ≥ 3 neutropenia. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Cabazitaxel can interact with other medicines that affect its metabolism or increase myelosuppression.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise cabazitaxel exposure and toxicity. - Concurrent myelosuppressive agents (e.g., cyclophosphamide): increase risk of severe bone‑marrow suppression. - Live vaccines: risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce drug efficacy. - Anticoagulants (e.g., warfarin, DOACs): monitor for bleeding complications. - Antiemetics with QT‑prolonging potential: observe cardiac rhythm.